New Products

NEW YORK — The makers of a pill bottle that uses wireless technology to keep patients adherent won the grand prize at a recent healthcare innovation contest.

AdhereTech developers Josh Stein, John Langhauser and Mike Morena will receive $50,000 in prize money as winners in the Healthcare Innovation World Cup, an international diabetes innovation challenge funded by Boehringer Ingelheim and organized by HITLAB.

BATTLE CREEK, Mich. — MorningStar Farms, a Kellogg Company brand, today announced the addition of a Mediterranean-style veggie burger to the company's line of meatless burgers.

NEW YORK — Just in time for summer, Ouidad is set to launch its new line of Color Sense products designed to preserve and protect hair color from fading caused by sun exposure and other environmental factors that can damage hair.

SILVER SPRING, Md. — A new treatment for late-stage prostate cancer has received approval from the Food and Drug Administration.

The FDA announced Wednesday the approval of Bayer's Xofigo (radian Ra 223 dichloride) for men with symptomatic, castration-resistant prostate cancer that has spread to the bones but not other organs, also known as metastasis. The drug is designed for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

DALLAS — Kimberly-Clark on Wednesday announced the launch of Depend Guards and Shields, two products specifically designed for men with light bladder leakage, along with tips and tools from former professional football star Tony Siragusa in a new program called Guard Your Manhood. 

PITTSBURGH — The Food and Drug Administration has approved a generic migraine drug made by Mylan, the company said Wednesday.

Mylan announced the approval of zolmitriptan tablets in the 2.5 mg and 5 mg strengths. The drug maker plans to launch the product immediately.

The drug is a generic version of IPR Pharmaceuticals' Zomig and is used for the acute treatment of migraine in adults. Various versions of the drug had sales of $152.8 million during the 12-month period that ended in March, according to IMS Health.

NORTH WALES, Pa. — Teva Health Systems has launched a generic injectable drug for small-cell lung cancer, the company said Tuesday.

Teva, a subsidiary of Teva Pharmaceuticals, itself a subsidiary of Israel-based Teva Pharmaceutical Industries, announced the launch of topotecan injection in the 1 mg-per-1 mL strength, in 4 mL, single-dose vials.

The drug is a generic version of GlaxoSmithKline's Hycamtin.

DELRAY BEACH, Fla. — A new all-natural spray promises to not only cover up unwanted smells, but also eliminate them at the source, the company stated this week.

Squelch is an all-natural, non-toxic spray that is odorless. It is safe to use on skin, hair, clothes or any other source that may trap odors. Squelch also is hypoallergenic, does not stain or fade clothes and is environmentally friendly.